1482-50-4
1482-50-4
Chemical Structure
5β-Dihydrocortisol
- CAS No.: 1482-50-4
- Formula:C21H32O5
- Molecular Weight:364.48
IUPAC Name: (5R,8S,9S,10S,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: ACSFOIGNUQUIGE-AIPUTVCKSA-N
SMILES: C[C@@]1([C@@]2(O)C(CO)=O)[C@](CC2)([H])[C@@](CC[C@@](C3)([H])[C@@]4(CCC3=O)C)([H])[C@]4([H])[C@@H](O)C1
Biological Activity: 5β-Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5β-Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5β-Dihydrocortisol causes breast cancer cell apoptosis[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
5β-Dihydrocortisol | 99.86% | 5β-Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5β-Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5β-Dihydrocortisol causes breast cancer cell apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5β-Dihydrocortisol (Standard) | ≥98% | D-Psicose (Standard) is the analytical standard of D-Psicose. This product is intended for research and analytical applications. D-Psicose is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5β-Dihydrocortisol-d6 | 5β-Dihydrocortisol-d6 is the deuterium labeled 5β-Dihydrocortisol. 5β-Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5β-Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5β-Dihydrocortisol causes breast cancer cell apoptosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marver D, et, al. Dihydrocortisol: a potential mineralocorticoid. J Steroid Biochem. 1978 Jan;9(1):1-7. [Content Brief]
- [2]. Kallubai M, et, al. Spectroscopic evaluation of synthesized 5β-dihydrocortisol and 5β-dihydrocortisol acetate binding mechanism with human serum albumin and their role in anticancer activity. J Biomol Struct Dyn. 2019 Feb;37(3):623-640. [Content Brief]
- [3]. Southren AL, et, al. 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. Invest Ophthalmol Vis Sci. 1985 Mar;26(3):393-5. [Content Brief]
- [4]. Appanna N, et, al. Differential activity and expression of human 5β-reductase (AKR1D1) splice variants. J Mol Endocrinol. 2021 Mar;66(3):181-194. [Content Brief]
- [5]. Weinstein BI, et, al. Potentiation of glucocorticoid activity by 5 beta-dihydrocortisol: its role in glaucoma. Science. 1983 Oct 14;222(4620):172-3. [Content Brief]
